PRANAZEPIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H19FN4O2
Molecular Weight	438.4531
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=CC=C1C2=N[C@H](NC(=O)C3=CC4=C(N3)C=CC=C4)C(=O)N5CCC6=CC=CC2=C56

InChI

InChIKey=WKJDXKWFGJWGAS-XMMPIXPASA-N

InChI=1S/C26H19FN4O2/c27-19-10-3-2-8-17(19)22-18-9-5-7-15-12-13-31(23(15)18)26(33)24(29-22)30-25(32)21-14-16-6-1-4-11-20(16)28-21/h1-11,14,24,28H,12-13H2,(H,30,32)/t24-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C26H19FN4O2
Molecular Weight	438.4531
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7805132http://adisinsight.springer.com/drugs/800003071
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8680546

PRANAZEPIDE (FK480), a non-peptide CCK-A receptor antagonist developed in Japan. FK-480 was in phase II clinical trial for the treatment of pancreatitis or gastrointestinal disorders. No development was reported for Pancreatitis in Japan.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://adisinsight.springer.com/drugs/800003071 \| https://www.ncbi.nlm.nih.gov/pubmed/7805132	Antagonist 2778		0.4 nM [IC50]
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7805132	Binding Agent 1064		18.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pancreatitis 16 Sources: http://adisinsight.springer.com/drugs/800003071	Primary		Phase II 1132	Unknown Approved Use Unknown
Unknown 2578

PubMed

Title	Date	PubMed
Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.	1994 Oct	7805132

Patents

Sample Use Guides

In Vivo Use Guide

To study effect on CCK-8 induced inhbition of charcoal meal gastric emptying in mice, (R)-FK480 was administered orally. Administration of 0.32 mg/kg lead to 19.4% inhibition, ED50 was determined to be 0.672 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

(R)-FK480 inhibits bindng of 125I-CCK-8 to rat pancreatic membrane with IC50 of 18 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 04:53:38 GMT 2023` Edited by `admin` on `Sat Dec 16 04:53:38 GMT 2023`
Record UNII	10TO0RP68C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRANAZEPIDE

Official Name

English

PANAZEPIDE

Common Name

English

pranazepide [INN]

Common Name

English

PANAZEPIDE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C547